On October 15, 2020 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported the company’s participation at the Immuno Series US Virtual meeting which will be held online, October 15-16, 2020 (Press release, Personalis, OCT 15, 2020, View Source [SID1234568528]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Personalis will present "Maximizing immunotherapy biomarker discovery with a multidimensional tumor immunogenomics platform," featuring the Personalis universal cancer immunogenomics approach, ImmunoID NeXT. Kedar Hastak, PhD, will present for Personalis. His presentation will focus on the current challenges facing investigators in immuno-oncological translational research including maximizing data generation from a single sample and the analysis of complex data.
Dr. Hastak will discuss how more accurate, predictive biomarker analysis may assist in the selection of effective combinatorial immunotherapy treatments for patients. Additionally, the complexity of both the tumor and tumor microenvironment suggests a comprehensive approach is needed for robust characterization of the cancer ecosystem. By combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, the ImmunoID NeXT Platform provides a multidimensional view of the tumor and the tumor microenvironment (TME) from a single sample preparation. Dr. Hastak will feature a case study demonstrating the ability of this immunogenomics profiling platform to uncover tumor escape mechanisms and to identify composite biomarkers of potentially greater predictive capacity from patients treated with immune checkpoint blockade. Additionally, the presentation will highlight NeXT Liquid Biopsy, an exome-wide liquid biopsy approach combined with ImmunoID NeXT, to further explore critical areas of tumor biology.